Real-world drug survival of ixekizumab for psoriasis

被引：9
|
作者：
Lee, Erica B. [1 ]
Pithadia, Deeti J. [2 ]
Reynolds, Kelly A. [3 ]
Reddy, Shivani P. [4 ]
Egeberg, Alexander [5 ]
Wu, Jashin J. [6 ]
机构：
[1] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA
[2] Augusta Univ, Med Coll Georgia, Augusta, GA USA
[3] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[4] Kaiser Permanente Los Angeles Med Ctr, Dept Dermatol, Los Angeles, CA USA
[5] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Hellerup, Denmark
[6] Dermatol Res & Educ Fdn, Irvine, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 01期
关键词：
PLAQUE PSORIASIS; NONRESPONDERS; EFFICACY; SAFETY; TRIALS;
D O I：
10.1016/j.jaad.2019.01.034
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：270 / 272
页数：4
相关论文
共 50 条
  • [21] Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab
    Blauvelt, Andrew
    Shi, Nianwen
    Burge, Russel
    Malatestinic, William N.
    Lin, Chen-Yen
    Lew, Carolyn R.
    Zimmerman, Nicole M.
    Goldblum, Orin M.
    Zhu, Baojin
    Murage, Mwangi J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (04) : 927 - 935
  • [22] Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
    Blauvelt, Andrew
    Shi, Nianwen
    Burge, Russel
    Malatestinic, William N.
    Lin, Chen-Yen
    Lew, Carolyn R.
    Zimmerman, Nicole M.
    Goldblum, Orin M.
    Zhu, Baojin
    Murage, Mwangi J.
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 517 - 527
  • [23] Drug survival of apremilast in a real-world setting
    Kishimoto, Megumi
    Komine, Mayumi
    Kamiya, Koji
    Sugai, Junichi
    Ohtsuki, Mamitaro
    [J]. JOURNAL OF DERMATOLOGY, 2019, 46 (07): : 615 - 617
  • [24] Reply to: "Comment on 'Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study'''
    Chiricozzi, Andrea
    Torres, Tiago
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (03) : E83 - E83
  • [25] Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
    Schaeffer, Lisa
    Ben-Anaya, Nesrine
    Sorbe, Christina
    Rustenbach, Stephan Jeff
    Mrowietz, Ulrich
    Augustin, Matthias
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [26] Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience
    Distel, Julian
    Cazzaniga, Simone
    Seyed Jafari, S. Morteza
    Emelianov, Vladimir
    Schlapbach, Christoph
    Yawalkar, Nikhil
    Heidemeyer, Kristine
    [J]. DERMATOLOGY, 2022, 238 (02) : 267 - 275
  • [27] Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting
    Ogut, Neslihan Demirel
    Yildirim, Sema Koc
    Erbagci, Ece
    Hapa, Fatma Asli
    [J]. JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (11) : 6215 - 6224
  • [28] Treatment switching among psoriasis patients treated with ixekizumab, secukinumab, and adalimumab in real-world settings
    Blauvelt, A.
    Shi, N.
    Burge, R.
    Malatestinic, W. N.
    Lew, C. R.
    Zimmerman, N. M.
    Amato, D.
    Zhu, B.
    Murage, M. J.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 24 - 24
  • [29] COMPARISON OF SWITCHING PATTERNS AMONG PATIENTS WITH PSORIASIS USING IXEKIZUMAB OR SECUKINUMAB IN REAL-WORLD SETTINGS
    Blauvelt, A.
    Shi, N.
    Somani, N.
    Kern, S.
    Atiya, B.
    Burge, R.
    Ridenour, T.
    Zhu, B.
    Zimmerman, N.
    Murage, M.
    [J]. VALUE IN HEALTH, 2021, 24 : S17 - S18
  • [30] Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center
    Zeb, Lawangeen
    Mhaskar, Rahul
    Lewis, Suzanna
    Patel, Nishit S.
    Sadhwani, Divya
    Patel, Nupur
    Ekhlassi, Erfon
    Lu, Yuanyuan
    Seminario-Vidal, Lucia
    [J]. DERMATOLOGIC THERAPY, 2021, 34 (02)
12345